ATE302763T1 - Bicyclische cyclohexylamine und ihre verwendung als nmda-rezeptor antagonisten - Google Patents

Bicyclische cyclohexylamine und ihre verwendung als nmda-rezeptor antagonisten

Info

Publication number
ATE302763T1
ATE302763T1 AT01933173T AT01933173T ATE302763T1 AT E302763 T1 ATE302763 T1 AT E302763T1 AT 01933173 T AT01933173 T AT 01933173T AT 01933173 T AT01933173 T AT 01933173T AT E302763 T1 ATE302763 T1 AT E302763T1
Authority
AT
Austria
Prior art keywords
cyclohexylamines
bicyclic
receptor antagonists
nmda receptor
nmda
Prior art date
Application number
AT01933173T
Other languages
English (en)
Inventor
Sham Shridhar Nikam
Ian Leslie Scott
Brian Alan Sherer
Lawrence David Wise
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE302763T1 publication Critical patent/ATE302763T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
AT01933173T 2000-05-31 2001-05-08 Bicyclische cyclohexylamine und ihre verwendung als nmda-rezeptor antagonisten ATE302763T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20824100P 2000-05-31 2000-05-31
PCT/US2001/014763 WO2001092239A1 (en) 2000-05-31 2001-05-08 Biciclic cyclohexylamines and their use as nmda receptor antogonists

Publications (1)

Publication Number Publication Date
ATE302763T1 true ATE302763T1 (de) 2005-09-15

Family

ID=22773822

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01933173T ATE302763T1 (de) 2000-05-31 2001-05-08 Bicyclische cyclohexylamine und ihre verwendung als nmda-rezeptor antagonisten

Country Status (28)

Country Link
US (1) US6794402B2 (de)
EP (1) EP1286975B1 (de)
JP (1) JP2003535083A (de)
KR (1) KR20030007797A (de)
CN (1) CN1438996A (de)
AP (1) AP2002002697A0 (de)
AT (1) ATE302763T1 (de)
AU (1) AU2001259618A1 (de)
BG (1) BG107375A (de)
BR (1) BR0111301A (de)
CA (1) CA2409006A1 (de)
DE (1) DE60112924T2 (de)
DZ (1) DZ3361A1 (de)
EA (1) EA200201158A1 (de)
EE (1) EE200200667A (de)
ES (1) ES2245985T3 (de)
HR (1) HRP20021018A2 (de)
HU (1) HUP0302323A2 (de)
IL (1) IL153170A0 (de)
IS (1) IS6625A (de)
MA (1) MA26907A1 (de)
MX (1) MXPA02011926A (de)
NO (1) NO20025762L (de)
OA (1) OA12275A (de)
PL (1) PL359260A1 (de)
SK (1) SK16632002A3 (de)
WO (1) WO2001092239A1 (de)
ZA (1) ZA200209325B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02002749A (es) 2001-03-27 2002-10-28 Warner Lambert Co Derivados de ciclohexilamina como antagonistas del subtipo selectivo del n-metil-d-aspartato.
GB0116594D0 (en) * 2001-07-06 2001-08-29 Cancer Res Ventures Ltd Therapeutic compounds
DE10210779A1 (de) * 2002-03-12 2003-10-09 Merck Patent Gmbh Cyclische Amide
CN101675927A (zh) 2002-06-07 2010-03-24 科蒂科股份有限公司 治疗分子及方法-1
EP1572197B1 (de) 2002-12-20 2009-07-29 Cancer Research Technology Limited 4-(1-(sulfonyl)-1h-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone verbindungen und ihre analoge als therapeutische wirkstoffe
JP2008525439A (ja) * 2004-12-23 2008-07-17 ボイジャー・ファーマシューティカル・コーポレーション アルツハイマー病の治療のための酢酸ロイプロリド及びアセチルコリンエステラーゼインヒビターまたはｎｍｄａレセプターアゴニスト
JP5270943B2 (ja) * 2008-03-28 2013-08-21 大阪瓦斯株式会社 フルオレン誘導体およびこのフルオレン誘導体を用いたアミノ基含有フルオレン誘導体の製造方法
US9345848B2 (en) 2009-10-20 2016-05-24 Sima Patent Ve Lisanslama Hizmetleri Ltd. Sti. Dry powder inhaler
WO2011092293A2 (en) * 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
US9216954B2 (en) 2012-01-27 2015-12-22 National University Corporation University Of Toyama Serine racemase inhibitor
CN105153020A (zh) * 2015-07-20 2015-12-16 湖南华腾制药有限公司 一种芳香叠氮化合物的制备方法
CN105061254A (zh) * 2015-07-20 2015-11-18 湖南华腾制药有限公司 一种含溴叠氮化合物的合成方法
CN105001118A (zh) * 2015-07-20 2015-10-28 湖南华腾制药有限公司 一种含碘叠氮化合物的制备方法
CN105152966A (zh) * 2015-07-20 2015-12-16 湖南华腾制药有限公司 一种叠氮化合物的制备方法
WO2018033525A1 (en) * 2016-08-16 2018-02-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Agonists or partial agonists of the histamine site of the nmda receptor for use in the treatment of central nervous system diseases
CN107043335A (zh) * 2017-05-31 2017-08-15 湖南华腾制药有限公司 一种2‑氟苯基叠氮化合物的制备方法
WO2019043217A1 (en) * 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROBENZIMIDAZOLONES
CN113557235B (zh) 2019-03-06 2025-08-08 C4医药公司 用于药物治疗的杂环化合物
WO2025232878A1 (zh) * 2024-05-09 2025-11-13 苏州旺山旺水生物医药股份有限公司 一类含取代的苯基的胺类化合物、其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4438055A1 (de) * 1994-10-25 1996-05-02 Thomae Gmbh Dr K Ring- und N-substituierte N-Benzyl-cycloalkylamine, ihre Salze mit physiologisch verträglichen organischen oder anorganischen Säuren, Verfahren zur Herstellung dieser Verbindungen und diese enthaltende Arzneimittel
DE19812331A1 (de) 1998-03-20 1999-09-23 Merck Patent Gmbh Piperidinderivate
EP0982026B1 (de) * 1998-08-18 2006-05-17 F. Hoffmann-La Roche Ag Verwendung von Aryl-Cyclohexylamine Derivaten zur Herstellung von NMDA-Rezeptorblockern

Also Published As

Publication number Publication date
DZ3361A1 (fr) 2001-12-06
CN1438996A (zh) 2003-08-27
OA12275A (en) 2003-12-11
EE200200667A (et) 2004-06-15
WO2001092239A1 (en) 2001-12-06
KR20030007797A (ko) 2003-01-23
DE60112924D1 (de) 2005-09-29
PL359260A1 (en) 2004-08-23
AP2002002697A0 (en) 2002-12-31
IL153170A0 (en) 2003-06-24
DE60112924T2 (de) 2006-03-16
MA26907A1 (fr) 2004-12-20
NO20025762D0 (no) 2002-11-29
EP1286975A1 (de) 2003-03-05
JP2003535083A (ja) 2003-11-25
CA2409006A1 (en) 2001-12-06
ZA200209325B (en) 2004-02-16
HUP0302323A2 (hu) 2003-10-28
SK16632002A3 (sk) 2003-08-05
EA200201158A1 (ru) 2003-04-24
BG107375A (bg) 2003-09-30
ES2245985T3 (es) 2006-02-01
HRP20021018A2 (en) 2004-02-29
EP1286975B1 (de) 2005-08-24
AU2001259618A1 (en) 2001-12-11
NO20025762L (no) 2003-01-09
US20030236252A1 (en) 2003-12-25
US6794402B2 (en) 2004-09-21
MXPA02011926A (es) 2003-04-22
BR0111301A (pt) 2003-06-10
IS6625A (is) 2002-11-18

Similar Documents

Publication Publication Date Title
ATE302763T1 (de) Bicyclische cyclohexylamine und ihre verwendung als nmda-rezeptor antagonisten
DE60106607D1 (de) Substituierte 1-aminoalkyl-lactame und ihre verwendung als muscarinrezeptor antagonisten
DE69925730D1 (de) 4-benzyl-piperidin-alkylsulfoxid-heterozyklen und ihre verwendung als subtyp-selektive nmda rezeptor antagonisten
DE60015296D1 (de) Indolderivate und ihre verwendung als mcp-1 rezeptor antagonisten
DE602005002030D1 (de) Benzimidazolderivate und ihre verwendung als antagonisten des a ii rezeptors
DE60112322D1 (de) Aminothiazole und deren verwendung als adenosinrezeptorantagonisten
DE60324767D1 (de) Fluoro substituierte cycloalkanindole und deren verwendung als prostaglandin d2 rezeptor antagonisten
IS7801A (is) Púrín efnasambönd og notkun þeirra sem kannabinóíð viðtaka bindla
DE60114413D1 (de) Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten
NO20051871D0 (no) Opioid reseptorantagonister
CY2015029I1 (el) Τρικυκλικοι ανταγωνιστες υποδοχεα θρομβινης
DE60208661D1 (de) Diaminothiazole und ihre verwendung als cyclinabhängige kinase inhibitoren
ATE329906T1 (de) Substituierte 2-anilino-benzimidazole und ihre verwendung als nhe-inhibitoren
DE60216229D1 (de) Il-8-rezeptorantagonisten
DE60321958D1 (de) Indazolderivate und ihre verwendung als crf antagonisten
ATE438395T1 (de) Pyrazolderivate und ihre verwendung als orexin- rezeptor-antagonisten
DE59914921D1 (de) 1-(3 -heteroarylpropyl- oder -prop -2-enyl) -4-benzylpiperidine als nmda-rezeptor-antagonisten
ATE418542T1 (de) Als ccr5-antagonisten verwendbare aryloxim- piperazine
DE60317632D1 (de) 2-oxazolamine und ihre verwendung als 5-ht2b-rezeptor-antagonisten
PT1448566E (pt) Antagonistas do receptor quimioquina e metodos de utilizacao do mesmo
NO20033223L (no) Histamin-reseptor antagonister
ATE370932T1 (de) Ccr-3-rezeptorantagonisten vii
DE60209885D1 (de) Crf receptor antagonisten
AU2002363582A1 (en) Piperazine bis-amide derivatives and their use as antagonists of the orexin receptor

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties